# Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

> **NCT00039780** · PHASE3 · COMPLETED · sponsor: **BioNumerik Pharmaceuticals, Inc.** · enrollment: 764 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Diseases
- Metastases, Neoplasm

## Interventions

- **DRUG:** BNP7787
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00039780
- **Lead sponsor:** BioNumerik Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2006-10
- **Final completion:** 2014-09
- **Target enrollment:** 764 (ACTUAL)
- **Last updated:** 2022-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039780, "Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00039780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*